Royalty Pharma plc (NASDAQ:RPRX) Receives $43.00 Average Target Price from Analysts

Shares of Royalty Pharma plc (NASDAQ:RPRX) have been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $43.00.

Several research firms have issued reports on RPRX. StockNews.com cut Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. UBS Group downgraded Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 price objective for the company. in a research report on Monday, June 3rd. Finally, Bank of America decreased their price objective on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a report on Friday, April 12th.

Royalty Pharma Stock Performance

RPRX opened at $26.37 on Wednesday. Royalty Pharma has a twelve month low of $25.92 and a twelve month high of $31.66. The firm has a market capitalization of $15.75 billion, a PE ratio of 19.68, a PEG ratio of 3.44 and a beta of 0.47. The company has a current ratio of 12.52, a quick ratio of 12.52 and a debt-to-equity ratio of 0.62. The firm’s 50-day moving average price is $27.36 and its 200 day moving average price is $28.49.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.02. Royalty Pharma had a return on equity of 22.94% and a net margin of 35.70%. The company had revenue of $568.00 million for the quarter, compared to analyst estimates of $671.45 million. During the same quarter in the previous year, the company posted $1.60 earnings per share. As a group, sell-side analysts expect that Royalty Pharma will post 4.03 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 17th were given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.19%. The ex-dividend date of this dividend was Thursday, May 16th. Royalty Pharma’s dividend payout ratio is currently 62.69%.

Hedge Funds Weigh In On Royalty Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in RPRX. Fidelis Capital Partners LLC acquired a new stake in Royalty Pharma in the first quarter valued at $46,000. Allworth Financial LP increased its position in shares of Royalty Pharma by 76.7% during the fourth quarter. Allworth Financial LP now owns 1,684 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 731 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Royalty Pharma by 172.5% during the first quarter. GAMMA Investing LLC now owns 1,638 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 1,037 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Royalty Pharma by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,807 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 802 shares during the last quarter. Finally, Lindbrook Capital LLC boosted its position in shares of Royalty Pharma by 485.2% in the 4th quarter. Lindbrook Capital LLC now owns 2,411 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 1,999 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.